GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1Results posted

A Multiple-Dose Study of LY3502970 in Healthy Participants

A Phase 1 Multiple Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of LY3502970 in Fed and Fasted Healthy Participants

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18.5-35•Healthy volunteers

Primary endpoints

•PK: Maximum Observed Concentration (Cmax) of LY3502970•PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24)•Cmax (Tmax) of LY3502970

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05110794

Org study ID18277

Secondary IDJ2A-MC-GZGJEli Lilly and Company

Timeline

Milestones

Study start2021-11-05actual

Study first posted2021-11-08actual

Primary completion2022-02-10actual

Study completion2022-02-10actual

Last update posted2026-05-26actual

Results first posted2026-05-26actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age21 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Are overtly healthy as determined by medical evaluation.

•Participants with body weight of 45 kilograms (kg) or more and body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m²).

Exclusion criteria

•Participants who have an abnormal blood pressure and/or pulse rate, deemed to be clinically significant by the investigator at screening.

•Participants who used or intend to use over-the-counter (OTC) or prescription medication and/or herbal/vitamin/traditional medicines or mineral supplements that may affect the safety or objectives of the study, within 14 days prior to dosing and for the duration of the study. Paracetamol and Covid-19 vaccinations are permitted.

•Participants who are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study.

•Participants who show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies. A negative test within 6 months of screening would not need to be repeated.

•Participants who show evidence of hepatitis C and/or positive hepatitis C antibody. A negative test within 6 months of screening would not need to be repeated.

•Participants who show evidence of hepatitis B, positive hepatitis B surface antigen, and/or positive hepatitis B core antibody. A negative test within 6 months of screening would not need to be repeated.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

6 endpoints

Primary/registry result

PK: Maximum Observed Concentration (Cmax) of LY3502970

Time frame:PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanograms per milliliter (ng/mL)	95% CI
16 mg LY3502970 (Fasted)	80.5	—
16 mg LY3502970 (Fed)	67.5	—

Primary/registry result

PK: Area Under the Concentration-time Curve From 0 to 24 Hour (AUC0-24) of LY3502970

Time frame:PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)

concentration, descriptive

Posted result

Group	Value (geometric_mean), ng*hour(h)/mL	95% CI
16 mg LY3502970 (Fasted)	1200	—
16 mg LY3502970 (Fed)	1050	—

Primary/registry result

Time to Maximum Observed Concentration (Tmax) of LY3502970

Time frame:PK: Day 28: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 1); Day 35: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, and 24h Postdose (Test Period 2)

time to event, event

Posted result

Group	Value (median), hour	95% CI
16 mg LY3502970 (Fasted)	8.0	4.00 – 16.00
16 mg LY3502970 (Fed)	8.00	4.00 – 24.00

Primary/protocol endpoint

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

Time frame:Predose up to 41 days postdose

Cmax

concentration, descriptive

Primary/protocol endpoint

PK: Area Under the Concentration-time curve from 0 to 24 hour (AUC0-24) of LY3502970

Time frame:Predose up to 41 days postdose

concentration, descriptive

Primary/protocol endpoint

PK: Time to Maximum Observed Concentration (Tmax) of LY3502970

Time frame:Predose up to 41 days postdose

Tmax

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.
Diabetes therapy : research, treatment and education of diabetes and related disorders2024 Apr (month)PMID38402332doi:10.1007/s13300-024-01554-1via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.